Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000–2013)

J. Gillem, Michelle Giuffrida, E. Krick

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Medical records of 22 dogs treated with carboplatin (n = 8) or carboplatin and cytarabine (n = 14) chemotherapy for relapsed or refractory lymphoma between 2000 and 2013 were retrospectively reviewed. The clinical response rate was 18.2% (4/22). Median time to progression was 18 days (56 for responders; 12 for non-responders, P = 0.0006). Median overall survival time was 28 days (109 for responders; 21 for non-responders, P = 0.0007). Thrombocytopenia and neutropenia occurred in 84.2% (16/19) and 52.6% (10/19), respectively. Grade IV thrombocytopenia and neutropenia occurred in 56.3% (9/16) and 60.0% (6/10), respectively. Dogs that received both drugs were more likely to become neutropenic (P = 0.022) or thrombocytopenic (P = 0.001) than dogs receiving carboplatin alone. All responders received both drugs giving a 28.6% (4/14) response rate for the combination. Although some dogs responded to the combination, toxicity was high and the responses were not durable. With adequate supportive care, this protocol may be an acceptable rescue option for some dogs.

Original languageEnglish (US)
Pages (from-to)400-410
Number of pages11
JournalVeterinary and Comparative Oncology
Volume15
Issue number2
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Carboplatin
Cytarabine
lymphoma
drug therapy
Lymphoma
Dogs
toxicity
Drug Therapy
dogs
neutropenia
thrombocytopenia
Neutropenia
Thrombocytopenia
drugs
Pharmaceutical Preparations
Medical Records

Keywords

  • canine
  • carboplatin
  • chemotherapy
  • cytarabine
  • lymphoma
  • rescue

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000–2013). / Gillem, J.; Giuffrida, Michelle; Krick, E.

In: Veterinary and Comparative Oncology, Vol. 15, No. 2, 01.06.2017, p. 400-410.

Research output: Contribution to journalArticle

@article{8bacd7318a764b868e6683b0c7f995a8,
title = "Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000–2013)",
abstract = "Medical records of 22 dogs treated with carboplatin (n = 8) or carboplatin and cytarabine (n = 14) chemotherapy for relapsed or refractory lymphoma between 2000 and 2013 were retrospectively reviewed. The clinical response rate was 18.2{\%} (4/22). Median time to progression was 18 days (56 for responders; 12 for non-responders, P = 0.0006). Median overall survival time was 28 days (109 for responders; 21 for non-responders, P = 0.0007). Thrombocytopenia and neutropenia occurred in 84.2{\%} (16/19) and 52.6{\%} (10/19), respectively. Grade IV thrombocytopenia and neutropenia occurred in 56.3{\%} (9/16) and 60.0{\%} (6/10), respectively. Dogs that received both drugs were more likely to become neutropenic (P = 0.022) or thrombocytopenic (P = 0.001) than dogs receiving carboplatin alone. All responders received both drugs giving a 28.6{\%} (4/14) response rate for the combination. Although some dogs responded to the combination, toxicity was high and the responses were not durable. With adequate supportive care, this protocol may be an acceptable rescue option for some dogs.",
keywords = "canine, carboplatin, chemotherapy, cytarabine, lymphoma, rescue",
author = "J. Gillem and Michelle Giuffrida and E. Krick",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/vco.12176",
language = "English (US)",
volume = "15",
pages = "400--410",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000–2013)

AU - Gillem, J.

AU - Giuffrida, Michelle

AU - Krick, E.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Medical records of 22 dogs treated with carboplatin (n = 8) or carboplatin and cytarabine (n = 14) chemotherapy for relapsed or refractory lymphoma between 2000 and 2013 were retrospectively reviewed. The clinical response rate was 18.2% (4/22). Median time to progression was 18 days (56 for responders; 12 for non-responders, P = 0.0006). Median overall survival time was 28 days (109 for responders; 21 for non-responders, P = 0.0007). Thrombocytopenia and neutropenia occurred in 84.2% (16/19) and 52.6% (10/19), respectively. Grade IV thrombocytopenia and neutropenia occurred in 56.3% (9/16) and 60.0% (6/10), respectively. Dogs that received both drugs were more likely to become neutropenic (P = 0.022) or thrombocytopenic (P = 0.001) than dogs receiving carboplatin alone. All responders received both drugs giving a 28.6% (4/14) response rate for the combination. Although some dogs responded to the combination, toxicity was high and the responses were not durable. With adequate supportive care, this protocol may be an acceptable rescue option for some dogs.

AB - Medical records of 22 dogs treated with carboplatin (n = 8) or carboplatin and cytarabine (n = 14) chemotherapy for relapsed or refractory lymphoma between 2000 and 2013 were retrospectively reviewed. The clinical response rate was 18.2% (4/22). Median time to progression was 18 days (56 for responders; 12 for non-responders, P = 0.0006). Median overall survival time was 28 days (109 for responders; 21 for non-responders, P = 0.0007). Thrombocytopenia and neutropenia occurred in 84.2% (16/19) and 52.6% (10/19), respectively. Grade IV thrombocytopenia and neutropenia occurred in 56.3% (9/16) and 60.0% (6/10), respectively. Dogs that received both drugs were more likely to become neutropenic (P = 0.022) or thrombocytopenic (P = 0.001) than dogs receiving carboplatin alone. All responders received both drugs giving a 28.6% (4/14) response rate for the combination. Although some dogs responded to the combination, toxicity was high and the responses were not durable. With adequate supportive care, this protocol may be an acceptable rescue option for some dogs.

KW - canine

KW - carboplatin

KW - chemotherapy

KW - cytarabine

KW - lymphoma

KW - rescue

UR - http://www.scopus.com/inward/record.url?scp=84951955481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951955481&partnerID=8YFLogxK

U2 - 10.1111/vco.12176

DO - 10.1111/vco.12176

M3 - Article

C2 - 26463827

AN - SCOPUS:84951955481

VL - 15

SP - 400

EP - 410

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 2

ER -